FDA Clears Update of AI-Enabled Imaging Contour Models
Updates to Contour ProtegeAI 4.0 reportedly include enhanced algorithms for radiation oncology segmentation and molecular radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated version of Contour ProtegeAI® 4.0 (MIM Software), a platform that provides automated deep learning segmentation for organs at risk (OARs).
Contour ProtegeAI 4.0 offers improved algorithms for radiation oncology as well as improvements for molecular radiotherapy, according to MIM Software.
“Over the past several months, the MIM Software team has worked hard to focus this new version on improving our contouring performance,” noted Jay Obman, a product manager at MIM Software, Inc. “The initial testing has shown a good improvement in our overall contour quality, and I’m excited for our users to reap the benefits of those improvements as well as some new contours we’ve added.”
The company adds that the software facilitates standardized, efficient workflows and provides automated preparation for physician target volume (PTV) contouring. Contour ProtegeAI 4.0 also integrates with Eclipse™, RayStation®, Monaco® and Pinnacle, according to MIM Software.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
